LXRX

Lexicon Pharmaceuticals Inc

LXRX, USA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

https://www.lexpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LXRX
stock
LXRX

Lexicon Pharmaceuticals (Nasdaq: LXRX) publishes ACSL5 obesity data supporting LX9851 Stock Titan

Read more →
LXRX
stock
LXRX

A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) setenews.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$2.88

Analyst Picks

Strong Buy

1

Buy

2

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.93

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-10.63 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-6.20 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-168.05 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Medium

0.71

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 82.79% of the total shares of Lexicon Pharmaceuticals Inc

1.

Artal Group S A

(37.4741%)

since

2025/06/30

2.

Siren, L.L.C.

(10.7097%)

since

2025/06/30

3.

FMR Inc

(10.4947%)

since

2025/06/30

4.

Fidelity Growth Compy Commingled Pl S

(4.9767%)

since

2025/07/31

5.

Fidelity Growth Company Fund

(3.4085%)

since

2025/07/31

6.

Vanguard Group Inc

(2.4356%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(1.3859%)

since

2025/07/31

8.

Schonfeld Strategic Advisors LLC

(1.2593%)

since

2025/06/30

9.

Fidelity Growth Company K6

(1.0889%)

since

2025/07/31

10.

BlackRock Inc

(0.9231%)

since

2025/06/30

11.

Fidelity Series Growth Company

(0.8901%)

since

2025/07/31

12.

Sessa Capital IM LP

(0.8255%)

since

2025/06/30

13.

GSA Capital Partners LLP

(0.7789%)

since

2025/06/30

14.

Atlantic Trust Group, LLC

(0.6743%)

since

2025/06/30

15.

Geode Capital Management, LLC

(0.6543%)

since

2025/06/30

16.

Vanguard Institutional Extnd Mkt Idx Tr

(0.5487%)

since

2025/07/31

17.

Millennium Management LLC

(0.4522%)

since

2025/06/30

18.

Fidelity Select Biotechnology

(0.4179%)

since

2025/07/31

19.

AQR Capital Management LLC

(0.3859%)

since

2025/06/30

20.

Fidelity Extended Market Index

(0.2754%)

since

2025/07/31

21.

Charles Schwab Investment Management Inc

(0.243%)

since

2025/06/30

22.

Schwab US Small-Cap ETF™

(0.2429%)

since

2025/08/30

23.

State Street Corp

(0.2253%)

since

2025/06/30

24.

Jane Street Group LLC

(0.2214%)

since

2025/06/30

25.

Hennion & Walsh Asset Management Inc

(0.2183%)

since

2025/06/30

26.

Royal Bank of Canada

(0.2131%)

since

2025/06/30

27.

Susquehanna International Group, LLP

(0.2079%)

since

2025/06/30

28.

Vanguard Health Care ETF

(0.1549%)

since

2025/07/31

29.

Monaco Asset Management

(0.1463%)

since

2025/06/30

30.

HRT FINANCIAL LLC

(0.1344%)

since

2025/06/30

31.

Extended Equity Market Fund K

(0.1085%)

since

2025/06/30

32.

Invesco RAFI US 1500 Small-Mid ETF

(0.0932%)

since

2025/08/29

33.

Fidelity Total Market Index

(0.091%)

since

2025/07/31

34.

Fidelity Nasdaq Composite Index

(0.0734%)

since

2025/07/31

35.

Fidelity Series Total Market Index

(0.0723%)

since

2025/07/31

36.

Spartan Extended Market Index Pool F

(0.0633%)

since

2025/07/31

37.

Northern Trust Extended Eq Market Idx

(0.0577%)

since

2025/06/30

38.

NT Ext Equity Mkt Idx Fd - L

(0.0577%)

since

2025/06/30

39.

iShares Nasdaq US Biotech ETF USD Acc

(0.0575%)

since

2025/08/31

40.

NT Ext Equity Mkt Idx Fd - NL

(0.0461%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.04

EPS Estimate

-0.065

EPS Difference

0.025

Surprise Percent

38.4615%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.